|Bid||72.01 x 1300|
|Ask||72.02 x 1300|
|Day's range||71.86 - 72.43|
|52-week range||68.44 - 81.68|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||32.81|
|Earnings date||28 Oct 2021|
|Forward dividend & yield||2.60 (3.61%)|
|Ex-dividend date||14 Sep 2021|
|1y target est||93.21|
Dr. Cedric Dark, Assistant Professor at Baylor College of Medicine & Board Member with Doctors for America, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Here's a rundown of three such names that also happen to be components in the Dow Jones Industrial Average (DJINDICES: ^DJI). While shares of Merck & Co. (NYSE: MRK) participated in the initial rebound rally in March of last year, it dropped out of the effort by April and has been a laggard ever since. In fact, Merck's stock is a mere 14% above its March-2020 low, and down 17% from its pre-pandemic peak.